Pazopanib

Generic Name: Pazopanib

Brand Names: Votrient

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₇O_₂S

CAS Number: 444731-52-6

Unique Ingredient Identifier: 7RN5DR86CK

Background: Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication: Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer

Clinical Trials

Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

Phase 3

Completed

Conditions: Sarcoma, Soft Tissue

Interventions: Drug: Placebo
Drug: PAZOPANIB

First Posted Date: 2008-09-16

Last Posted Date: 2013-08-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 369

Registration Number: NCT00753688

Locations: 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom

An Extension to Study MD7108240

Phase 2

Completed

Conditions: Macular Degeneration

Interventions: Drug: Pazopanib

First Posted Date: 2008-08-13

Last Posted Date: 2017-12-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 42

Registration Number: NCT00733304

Locations: 🇮🇹
GSK Investigational Site, Padova, Veneto, Italy

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Drug: topotecan
Drug: pazopanib

First Posted Date: 2008-08-12

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 68

Registration Number: NCT00732420

Locations: 🇳🇱
GSK Investigational Site, Utrecht, Netherlands

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Pazopanib

First Posted Date: 2008-08-08

Last Posted Date: 2015-05-20

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 57

Registration Number: NCT00731211

Locations: 🇺🇸
Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Baptist Hospital East, Louisville, Kentucky, United States

and more 14 locations

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Pazopanib (GW786034)
Drug: Doxorubicin
Drug: Epirubicin

First Posted Date: 2008-07-25

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 111

Registration Number: NCT00722293

Locations: 🇨🇭
GSK Investigational Site, St Gallen, Switzerland

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase 3

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Pazopanib
Drug: Sunitinib

First Posted Date: 2008-07-23

Last Posted Date: 2025-03-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1110

Registration Number: NCT00720941

Locations: 🇬🇧
Novartis Investigative Site, Swansea, United Kingdom

A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors

Phase 1

Completed

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: Pazopanib (GW786034)
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2008-05-16

Last Posted Date: 2017-11-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 22

Registration Number: NCT00678977

Locations: 🇬🇧
GSK Investigational Site, Newcastle Upon Tyne, Northumberland, United Kingdom

Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function

Phase 1

Completed

Conditions: Neoplasms
Lymphoma

First Posted Date: 2008-05-07

Last Posted Date: 2019-11-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT00674024

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

Phase 1

Completed

Conditions: Macular Degeneration

Interventions: Drug: pazopanib eye drops
Drug: Ketoconozole tablets

First Posted Date: 2008-04-16

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT00659555

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Phase 2

Completed

Conditions: Recurrent Thyroid Gland Carcinoma
Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7
Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7
Stage III Thyroid Gland Medullary Carcinoma AJCC v7
Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7
Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
Stage III Differentiated Thyroid Gland Carcinoma AJCC v7
Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7
Thyroid Gland Anaplastic Carcinoma
Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7

Interventions: Drug: Pazopanib Hydrochloride
Other: Laboratory Biomarker Analysis

First Posted Date: 2008-02-28

Last Posted Date: 2020-02-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 152

Registration Number: NCT00625846

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States
🇸🇬
National University Hospital Singapore, Singapore, Singapore

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy